Lack of association of the codon 12 polymorphism of the peroxisome proliferator-activated receptor γ gene with breast cancer and body mass

被引:42
作者
Memisoglu, A
Hankinson, SE
Manson, JE
Colditz, GA
Hunter, DJ
机构
[1] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
[2] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Channing Lab, Dept Med, Boston, MA 02115 USA
[4] Harvard Univ, Sch Med, Div Prevent Med, Dept Med, Boston, MA 02115 USA
[5] Brigham & Womens Hosp, Boston, MA 02115 USA
[6] Harvard Ctr Canc Prevent, Boston, MA USA
来源
PHARMACOGENETICS | 2002年 / 12卷 / 08期
关键词
PPAR; polymorphism; breast neoplasm; oestrogen;
D O I
10.1097/00008571-200211000-00003
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
A principal hypothesized mechanism underlying breast carcinogenesis involves oestrogen-induced cell proliferation. In addition to its well-established role in the transcriptional regulation of genes required for adipocyte differentiation, the peroxisome proliferator-activated receptor gamma (PPARgamma) may be involved in transcriptional down-regulation of aromatase, a key enzyme in oestrogen biosynthesis. Furthermore, specific agonists for PPARgamma induce differentiation and suppress markers of malignancy in breast cancer cells in vitro. We investigated the association of the Pro(12)Ala PPARgamma polymorphism with breast cancer in a case-control study nested within the prospective Nurses' Health Study. Included were 725 incident cases of breast cancer diagnosed after blood collection through 1996 and 953 matched controls. In addition to breast cancer, the association of the PPARgamma Pro(12)Ala polymorphism with breast cancer risk factors, body mass index (BMI), weight gain since age 18 years, plasma hormones [oestrone sulphate, oestrone, oestradiol, androstenedione, testosterone, dehydroepiandrosterone (DHEA) and DHEA sulphate] and plasma lipids (total cholesterol and high density lipoprotein) was analysed. No significant association was observed between PPARgamma Pro(12)Ala polymorphism and either incident breast cancer (odds ratio = 1.08, 95% confidence interval = 0.85-1.38 for Ala allele carriers compared to non-carriers), plasma hormones, plasma cholesterol, BMI, weight gain since age 18 years or waist-to-hip ratio. To our knowledge, this is the first study to investigate the role of the Pro(12)Ala PPARgamma polymorphism in cancer. We did not find evidence to support a role for this polymorphism in breast cancer susceptibility. Furthermore, similar to others, we did not find evidence to suggest that Pro(12)Ala PPARgamma polymorphism is directly associated with body mass or weight gain.
引用
收藏
页码:597 / 603
页数:7
相关论文
共 51 条
[1]  
ALLAIN CC, 1974, CLIN CHEM, V20, P470
[2]   The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes [J].
Altshuler, D ;
Hirschhorn, JN ;
Klannemark, M ;
Lindgren, CM ;
Vohl, MC ;
Nemesh, J ;
Lane, CR ;
Schaffner, SF ;
Bolk, S ;
Brewer, C ;
Tuomi, T ;
Gaudet, D ;
Hudson, TJ ;
Daly, M ;
Groop, L ;
Lander, ES .
NATURE GENETICS, 2000, 26 (01) :76-80
[3]   Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes - A 6-month randomized placebo-controlled dose-response study [J].
Aronoff, S ;
Rosenblatt, S ;
Braithwaite, S ;
Egan, JW ;
Mathisen, AL ;
Schneider, RL .
DIABETES CARE, 2000, 23 (11) :1605-1611
[4]  
Asou H, 1999, INT J ONCOL, V15, P1027
[5]   Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension [J].
Barroso, I ;
Gurnell, M ;
Crowley, VEF ;
Agostini, M ;
Schwabe, JW ;
Soos, MA ;
Maslen, GL ;
Williams, TDM ;
Lewis, H ;
Schafer, AJ ;
Chatterjee, VKK ;
O'Rahilly, S .
NATURE, 1999, 402 (6764) :880-883
[6]   Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-γ2 gene with obesity in two Caucasian populations [J].
Beamer, BA ;
Yen, CJ ;
Andersen, BE ;
Muller, D ;
Elahi, D ;
Cheskin, LJ ;
Andres, R ;
Roth, J ;
Shuldiner, AR .
DIABETES, 1998, 47 (11) :1806-1808
[7]  
Chang TH, 2000, CANCER RES, V60, P1129
[8]   Sibling-based association study of the PPARγ2 Pro12Ala polymorphism and metabolic variables in Chinese and Japanese hypertension families:: a SAPPHIRe study [J].
Chuang, LM ;
Hsiung, CA ;
Chen, YDI ;
Ho, LT ;
Sheu, WHH ;
Pei, D ;
Nakatsuka, CH ;
Cox, D ;
Pratt, RE ;
Lei, HH ;
Tai, TY .
JOURNAL OF MOLECULAR MEDICINE-JMM, 2001, 79 (11) :656-664
[9]   The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes [J].
Clement, K ;
Hereberg, S ;
Passinge, B ;
Galan, P ;
Varroud-Vial, M ;
Shuldiner, AR ;
Beamer, BA ;
Charpentier, G ;
Guy-Grand, B ;
Froguel, P ;
Vaisse, C .
INTERNATIONAL JOURNAL OF OBESITY, 2000, 24 (03) :391-393
[10]   The Pro12Ala variant of peroxisome proliferator-activated receptor-γ2 (PPAR-γ2) is associated with measures of obesity in Mexican Americans [J].
Cole, SA ;
Mitchell, BD ;
Hsueh, WC ;
Pineda, P ;
Beamer, BA ;
Shuldiner, AR ;
Comuzzie, AG ;
Blangero, J ;
Hixson, JE .
INTERNATIONAL JOURNAL OF OBESITY, 2000, 24 (04) :522-524